AllSight
Companies · QDEL · In Vitro & In Vivo Diagnostic Substances

QuidelOrtho Corp (QDEL)

QuidelOrtho Corp (QDEL) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

QuidelOrtho Corp (QDEL) stock — financials & valuation

Key numbers for QuidelOrtho Corp (QDEL): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 30/100 — a percentile rank of QuidelOrtho Corp’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$722.8M
P / S0.3×
EV / EBITDA8.3×
Gross margin44.6%
Operating margin-30.8%
Net margin-39.2%
Return on equity-59.1%
ROIC-18.5%
Revenue growth-2.5%
Debt / equity1.6×
Dividend yield0.0%

Is QuidelOrtho Corp overvalued? P/S looks undervalued vs its 5-year range; EV/EBITDA looks undervalued vs its 5-year range; P/B looks undervalued vs its 5-year range.

Independent of the events above — derived from QuidelOrtho Corp’s own financial statements and shown as context, never as advice.

Sep 23, 2026Covenant relief
QuidelOrtho secures covenant relief as weak demand strains deleveraging
Aug 6, 2026
Full-year outlook sharply cut as China weakness and soft respiratory demand deepen
Related companies in In Vitro & In Vivo Diagnostic Substances
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact